Ursodeoxycholic acid reduces lipid peroxidation and mucin secretagogue activity in gallbladder bile of patients with cholesterol gallstones

European Journal of Clinical Investigation

Volumn 38, Issue 9, 2008, Pages 634-639

  Jungst C ^b   Sreejayan, N ^a   Zundt B ^a   Muller I ^a   Spelsberg, F W ^a   Huttl T P ^a   Kullak Ublick, G A ^b   Del Pozo, R ^c   Jungst D ^a   Von Ritter, C ^d,e  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSIDAD CATÓLICA DE LA SANTÍSIMA CONCEPCIÓN   (Chile)

^d Triamed Kreisklinik   (Germany)

^e Triamed Kreisklinik ^*  (Germany)

Author keywords

Cell culture; Gallbladder bile; Gallstones; Lipid peroxidation; Mucin; Ursodeoxycholic acid

Indexed keywords

MALONALDEHYDE; MUCIN; PLACEBO; URSODEOXYCHOLIC ACID;

ADULT; AGED; ANIMAL CELL; ANIMAL CELL CULTURE; ANTIOXIDANT ACTIVITY; ARTICLE; BEDTIME DOSAGE; BILE COMPOSITION; CHOLECYSTECTOMY; CHOLESTEROL STONE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EPITHELIUM CELL; FEMALE; GALLBLADDER EPITHELIUM; HUMAN; LIPID PEROXIDATION; MALE; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; BILE; CHOLAGOGUES AND CHOLERETICS; DOUBLE-BLIND METHOD; FEMALE; GALLBLADDER; GALLSTONES; HUMANS; LIPID PEROXIDATION; MALE; MIDDLE AGED; MUCINS; PLACEBOS; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 49749095068     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2008.01995.x     Document Type: Article

References (32)

1. LaMont JT, Smith BF, Moore JRL. Role of gallbladder mucin in the pathophysiology of gallstones. Hepatology 1984 4 : 51S 6S.
2. Smith BF. Gallbladder mucin as a pronucleating agent for cholesterol monohydrate crystals in bile. Hepatology 1990 11 : 183 8.
3. Gallinger S, Taylor RD, Harvey PRC, Petrunka CN, Strasberg SM. Effect of mucous glycoprotein on nucleation time of human bile. Gastroenterology 1985 89 : 648 58.
4. Lee SP. Hypersecretion of mucus glycoprotein by the gallbladder epithelium in experimental cholelithiasis. J Pathol 1981 134 : 199 207.
5. Lee SP, LaMont JT, Carey MC. Role of gallbladder mucus hypersecretion in the evolution of cholesterol gallstones: studies in the prairie dog. J Clin Invest 1981 67 : 1712 23.
6. Wang HH, Afdhal NH, Gendler SJ, Wang DQ. Evidence that gallbladder epithelial mucin enhances cholesterol cholelithogenesis in MUC1 transgenic mice. Gastroenterology 2006 131 : 210 22.
7. Lee TJ, Smith BF. Bovine gallbladder mucin promotes cholesterol crystal nucleation from cholesterol-transporting vesicles in supersaturated model bile. J Lipid Res 1989 30 : 491 8.
8. Levy PF, Smith BF, LaMont JT. Human gallbladder mucin accelerates nucleation of cholesterol in artificial bile. Gastroenterology 1984 87 : 270 5.
9. Wilhelmi M, Jüngst C, Mock M, Meyer G, Zündt B, del Pozo R et al. Effect of gallbladder mucin on the crystallization of cholesterol in bile. Eur J Gastroenterol Hepatol 2004 16 : 1301 7.
10. Jüngst C, Kullak-Ublick GA, Jüngst D. Gallstone disease: Microlithiasis and sludge. Best Pract Res Clin Gastroenterol 2006 20 : 1053 62.
11. Jüngst C, Sreejayan N, Eder MI, von Stillfried N, Zündt B, Spelsberg FW et al. Lipid peroxidation and mucin secretagogue activity in bile of gallstone patients. Eur J Clin Invest 2007 37 : 731 6.
12. Ljubuncic P, Fuhrman B, Oiknine J, Aviram M, Bomzon A. Effect of deoxycholic acid and ursodeoxycholic acid on lipid peroxidation in cultured macrophages. Gut 1996 39 : 475 8.
13. Lapenna D, Ciofani G, Festi D, Neri M, Pierdomenico SD, Giamberardino MA et al. Antioxidant properties of ursodeoxycholic acid. Biochem Pharm 2002 64 : 1661 7.
14. Guarino MP, Cong P, Cicala M, Alloni R, Carotti S, Behar J. Ursodeoxycholic acid improves muscle contractility and inflammation in symptomatic gallbladders with cholesterol gallstones. Gut 2007 56 : 815 20.
15. Tera H. Stratification of human gallbladder bile in vivo. Acta Chir Scand Suppl 1960 256 : 4 85.
16. Smallwood RA, Jablonski P, McWatts K. Intermittent secretion of abnormal bile in patients with cholesterol gallstones. Br Med J 1972 4 : 263 6.
17. Holan KR, Holzbach RT, Hermann RE, Cooperman AM, Claffey WJ. Nucleation time: a key factor in the pathogenesis of cholesterol gallstone disease. Gastroenterology 1979 77 : 611 7.
18. Abell LL, Levy BB, Brodie BB, Kendall FE. A simplified method for the estimation of total cholesterol in serum and demonstration of its specificity. J Biol Chem 1952 195 : 357 66.
19. Fiske CH, Subbarow Y. The colorimetric determination of phosphorus. J Biol Chem 1925 66 : 375 400.
20. Talalay P. Enzymatic analysis of steroid hormones. Biochem Anal 1960 8 : 119 44.
21. Carey MC. Critical tables for calculating the cholesterol saturation of native bile. J Lipid Res 1978 19 : 945 55.
22. Fischer S, Berr F, Paumgartner G. Unchanged levels of keto bile acids in bile after cholecystectomy. Digestion 1991 48 : 202 9.
23. Miquel JF, Groen AK, Van Wijland MJA, del Pozo R, Eder MI, von Ritter C. Quantification of mucin in human gallbladder bile: a fast, specific and reproducible method. J Lipid Res 1995 36 : 2450 8.
24. Wong SH, Knight JA, Hopfer SM, Zaharia O, Leach CNJ, Sunderman FWJ. Lipoperoxides in plasma as measured by liquid-chromatographic separation of malondialdehyde-thiobarbituric acid adduct. Clin Chem 1987 33 : 214 20.
25. Klinkspoor JH, Kuver R, Savard CE, Oda D, Tytgat GNJ, Groen AK et al. Model bile salts accelerate mucin secretion by cultured dog gallbladder epithelial cells. Gastroenterology 1995 109 : 264 74.
26. Eder MI, Miquel JF, Jüngst D, Paumgartner G, von Ritter C. Reactive oxygen metabolites promote cholesterol crystal formation in model bile: role of lipid peroxidation. Free Radic Biol Med 1996 20 : 743 9.
27. Sreejayan N, von Ritter C. Effect of bile acids on lipid peroxidation: the role of iron. Free Rad Biol Med 1998 25 : 50 6.
28. Tomida S, Abei M, Yamaguchi T, Matsuzaki Y, Shoda J, Tanaka N et al. Long-term ursodeoxycholic acid therapy is associated with reduced risk of biliary pain and acute cholecystitis in patients with gallbladder stones: a cohort analysis. Hepatology 1999 30 : 6 13.
29. Venneman NG, Besselink MG, Keulemans YC, van Berge-Henegouwen GP, Boermeester MA, Broeders IA et al. Ursodeoxycholic acid exerts no beneficial effect in patients with symptomatic gallstones awaiting cholecystectomy. Hepatology 2006 43 : 1276 83.
30. Fischer S, Müller I, Zündt B, Jüngst C, Meyer G, Jüngst D. Ursodeoxycholic acid decreases viscosity and sedimentable fractions of gallbladder bile in patients with cholesterol gallstones. Eur J Gastroenterol Hepatol 2004 16 : 305 11.
31. Kano M, Shoda J, Irimura T, Ueda T, Iwasaki R, Urasaki T et al. Effects of long-term ursodeoxycholate administration on expression levels of secretory low-molecular-weight phospholipases A2 and mucin genes in gallbladders and biliary composition in patients with multiple cholesterol stones. Hepatology 1998 28 : 302 13.
32. Sharma BC, Agarwal DK, Dhiman RK, Baijal SS, Choudhuri G, Saraswat VA. Bile lithogenicity and gallbladder emptying in patients with microlithiasis: effect of bile acid therapy. Gastroenterology 1998 115 : 124 8.